TCL Archive CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely May 23, 2003
TCL Archive Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990 January 27, 1989
TCL Archive ACC Survey Preliminary Finding: Three Cancer DRG Categories “Clearly Underpaid Across The Board” January 25, 1985
TCL Archive ODAC’s Dilemma: Proposed Indication Created By Reliance On PSA Screening and Hormonal Treatment September 23, 2011
